Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• Sangthawan et al. (2015): Effects of zinc sulfate supplementation on cell-mediated immune response in head and neck cancer patients treated with radiation therapy  + (Refused the radiation therapy)
• Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial  + (Refused to swallow capsules n = 1 Epileptic seizure grade 4, discontinued therapy n = 1)
• Pace et al. (2003): Neuroprotective Effect of Vitamin E Supplementation in Patient Treated With Cisplatin Chemotherapy  + (Reported n=2 suspended Vitamin E supplementation after 1 month, Not seperated by arm: interrupted treatment after two or three cycles because of disease progression n=18)
• Moslemi et al. (2014): Oral zinc sulphate and prevention of radiation-induced oropharyngealmucositis in patients with head and neck cancers: A double blind, randomized controlled clinical trial  + (Sever mucositis and interruption of treatment)
• Liu et al. (2010): Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial  + (Showed distant metastases on posttherapy scans)
• Liu et al. (2010): Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial  + (Showed distant metastases on posttherapy scans)
• Kasseroller et al. (2003): Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer  + (Side effects)
• Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies  + (Side effects (n = 29, 14.6%), consent withdrawn (n = 8, 4%), death (n = 25, 68%))
• Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies  + (Side effects (n = 38, 19%); consent withdrawn (n = 19, 9.5%); death (n = 20, 10%))
• Portenoy et al. (2012): Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial  + (Side effects (n=20); consent withdrawn (n=4); progression of the disease (n=7))
• Lichtmann et al. (2018): Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain  + (Side effects (n=35); consent withdrawn (n = 13); death (n=27))
• Lichtmann et al. (2018): Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain  + (Side effects (n=40); consent withdrawn (n=18); death (n=27))
• Portenoy et al. (2012): Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial  + (Side effects (n=5); consent withdrawn (n=1); progression of the disease (n=7); other reasons (n=3))
• Portenoy et al. (2012): Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial  + (Side effects (n=6); consent withdrawn (n=5); progression of the disease (n=7); other reasons (n=3))
• Portenoy et al. (2012): Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial  + (Side effects (n=9); consent withdrawn (n=6); progression of the disease (n=7): no effect (n=1); other reasons (n=1); no follow-up (n=1))
• Freedland et al. (2020): A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2)  + (Started ADT treatment (n=2); withdrew (n=1); started radiation (n=1))
• Freedland et al. (2020): A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2)  + (Started ADT treatment (n=6); withdrew (n=1); lost to follow up (n=1))
• Ripamonti et al. (1998): A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation  + (Stopped receiving radiotherapy at the 4th week due to acute oral cavity toxicity (assessment at 1 month after ERT termination was not made))
• Ripamonti et al. (1998): A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation  + (Stopped receiving radiotherapy at the 4th week due to acute oral cavity toxicity (assessment at 1 month after ERT termination was not made))
• Paur et al. (2017): Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA  + (Surgery (n=1))
• Nguyen et al. (2012): Randomized, Double-Blind, Placebo-Controlled Trial of Polyphenon E in Prostate Cancer Patients before Prostatectomy: Evaluation of Potential Chemopreventive Activities  + (Surgery cancelled + all participants: missing data for some of the endpoints due to the inability to collect some of the specimens or inadequate specimens for analysis; missing rate ranged from 2% (immunohistochemical tissue markers) to 23% (8-OHdG))
• Nguyen et al. (2012): Randomized, Double-Blind, Placebo-Controlled Trial of Polyphenon E in Prostate Cancer Patients before Prostatectomy: Evaluation of Potential Chemopreventive Activities  + (Surgery cancelled + all participants: missing data for some of the endpoints due to the inability to collect some of the specimens or inadequate specimens for analysis; missing rate ranged from 2% (immunohistochemical tissue markers) to 23% (8-OHdG))
• Sun et al. (2016): A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy  + (The safety analysis set contained 236 pati … The safety analysis set contained 236 patients, 118 in the intervention and 118 in the placebo arm. The full analysis set (FAS) contained 225 patients, 109 in the intervention and 116 in the placebo arm. The per-protocol set (PPS) contained 203 patients, 95 in the intervention and 108 in the placebo arm.e intervention and 108 in the placebo arm.)
• Sun et al. (2016): A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy  + (The safety analysis set contained 236 pati … The safety analysis set contained 236 patients, 118 in the intervention and 118 in the placebo arm. The full analysis set (FAS) contained 225 patients, 109 in the intervention and 116 in the placebo arm. The per-protocol set (PPS) contained 203 patients, 95 in the intervention and 108 in the placebo arm.e intervention and 108 in the placebo arm.)
• Stephenson et al. (2017): Partner-delivered reflexology: Effects on cancer pain and anxiety.  + (Unable to answer the preintervention visual analog scale and was too agitated to answer any postintervention questions)
• Stephenson et al. (2017): Partner-delivered reflexology: Effects on cancer pain and anxiety.  + (Unable to receive the intervention because they were too ill)

• Azizi et al. (2015): Efficacy of Topical and Systemic Vitamin E in Preventing Chemotherapy-induced Oral Mucositis  + (Various reasons (death, severe mucositis, noncompliance, etc.))
• Azizi et al. (2015): Efficacy of Topical and Systemic Vitamin E in Preventing Chemotherapy-induced Oral Mucositis  + (Various reasons (death, severe mucositis, noncompliance, etc.))
• Azizi et al. (2015): Efficacy of Topical and Systemic Vitamin E in Preventing Chemotherapy-induced Oral Mucositis  + (Various reasons (death, severe mucositis, noncompliance, etc.))

• Lin et al. (2006): Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study  + (Voluntary withdrawal)
• Lin et al. (2006): Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study  + (Voluntary withdrawal)
• Lin et al. (2008): Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: a double-blinded randomized study  + (Voluntary withdrawal)
• Lin et al. (2008): Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: a double-blinded randomized study  + (Voluntary withdrawal)
• Su et al. (2004): Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms  + (Withdrawing from the study because of difficulty in adhering to the four times daily oral care regimen)
• Delanian et al. (2003): Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis  + (Withdrawn (changed mind before study))
• Delanian et al. (2003): Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis  + (Withdrawn (intercurrent disease))
• Paur et al. (2017): Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA  + (Withdrew consent (n=1); hospital switch (n=1); postponed surgery (n=1))
• Cohen et al. (2018): Favorable Effects of a Ketogenic Diet on Physical Function, Perceived Energy, and Food Cravings in Women with Ovarian or Endometrial Cancer: A Randomized, Controlled Trial  + (Withdrew due to scheduling conflicts (n=6); not separated by arm: no longer wishing to comply with dietary requirements (n=3); cancer recurrence (n=3); death (n=2))
• Cohen et al. (2018): Favorable Effects of a Ketogenic Diet on Physical Function, Perceived Energy, and Food Cravings in Women with Ovarian or Endometrial Cancer: A Randomized, Controlled Trial  + (Withdrew due to scheduling conflicts (n=6); not separated by arm: no longer wishing to comply with dietary requirements (n=3); cancer recurrence (n=3); death (n=2))
• Hejazi et al. (2013): A pilot clinical trial of radioprotective effects of curcumin supplementation in patients with prostate cancer  + (Withdrew during intervention)
• Hejazi et al. (2013): A pilot clinical trial of radioprotective effects of curcumin supplementation in patients with prostate cancer  + (Withdrew during intervention)
• Hejazi et al. (2016): Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study  + (Withdrew during intervention)
• Hejazi et al. (2016): Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study  + (Withdrew during intervention)
• Barton et al. (2013): The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9  + (Withdrew for personal reasons n=15 Adverse Events n=5)
• Barton et al. (2013): The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9  + (Withdrew for personal reasons n=18 Adverse Events n=5)
• Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial  + (Withdrew for reasons other than study agent related adverse events)
• Mayne et al. (2001): Randomized Trial of Supplemental beta-Carotene to Prevent Second Head and Neck Cancer  + (lost to follow-up)
• Mayne et al. (2001): Randomized Trial of Supplemental beta-Carotene to Prevent Second Head and Neck Cancer  + (lost to follow-up)
• Minchom et al. (2014): An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of (...)  + (n = 4 did not received treatment - transferred care: 1 - myocardial infarction prior to chemotherapy: 1 - became eligible for cisplatin: 2)
• Sangthawan et al. (2013): A randomized double-blind, placebo-controlled trial of zinc sulfate supplementation for alleviation of radiation-induced oral mucositis and pharyngitis in head and neck cancer patients  + (n=1 died during the course of radiation, n=1 denied radiation therapy, n=1 left the study due to personal reason)
• Attia et al. (2008): Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer  + (n=1 elevated serum testosterone at baseline, n=1 use of digoxin discovered before treatment began (one), n=1 received treatment and discovered to have an elevated baseline serum testosterone level, n=4 withdrawn before first post-baseline imaging studies)
• Urashima et al. (2019): Effect of Vitamin D Supplementation on Relapse-Free Survival Among Patients With Digestive Tract Cancers The AMATERASU Randomized Clinical Trial  + (n=1 lost to follow-up within 6 month, n=23 stopped study medication (n=14 for nonmedical reasons, n=9 for medical reasons))
• Ribeiro et al. (2017): Effects of zinc supplementation on fatigue and quality of life in patients with colorectal cancer  + (n=11 chemotherapy was not indicated, n=3 refused chemotherapy)